挺进美女教师的蜜桃肥臀视频-同性恋一级片-同性情a三级a三级a三级-同性做爰猛烈全过程-91丨porny丨国产麻豆-91丨porny丨国产入口

BIOHIT HealthCare     
必歐瀚(Biohit)公司致力研制和生產(chǎn)在醫(yī)療領(lǐng)域、研究領(lǐng)域及商業(yè)實(shí)驗(yàn)室中使用的移液器產(chǎn)品與體外診斷檢測(cè)系統(tǒng)必歐瀚(Biohit)公司的診斷產(chǎn)品范圍包括GastroPanel和GastroView檢測(cè)，通過(guò)采集病人血液樣品，對(duì)幽門(mén)螺桿菌感染和萎縮性胃炎進(jìn)行檢測(cè)，并能對(duì)胃癌、消化性潰瘍、胃食管返流及其并發(fā)癥(維生素B12、鈣和鐵缺乏)、Barrett食管病等進(jìn)行快速篩查。
必歐瀚(Biohit)可提供多種ELISA檢測(cè)，乳糖不耐癥和幽門(mén)螺桿菌感染快速檢測(cè)以及結(jié)腸癌篩查層析法快速檢測(cè)。必歐瀚(Biohit)還開(kāi)發(fā)和制造適用于癌癥診斷的單克隆抗體，并可以用于制造免疫診斷試劑盒。
除了移液器和診斷試劑，必歐瀚(Biohit)的產(chǎn)品范圍還包括適用于免疫測(cè)定分析的各種酶標(biāo)儀洗板機(jī)和軟件。必歐瀚(Biohit)還可提供檢測(cè)儀器維護(hù)、校準(zhǔn)和培訓(xùn)服務(wù)以及進(jìn)行診斷檢測(cè)的服務(wù)實(shí)驗(yàn)室。
必歐瀚(Biohit)產(chǎn)品的新增項(xiàng)目包括用于消除來(lái)自胃腸道和食品的致癌乙醛的功能性食品。必歐瀚(Biohit)公司總部位于芬蘭首都赫爾辛基，制造工廠位于芬蘭的科亞尼及赫爾辛基。必歐瀚(Biohit)公司已于1999年在赫爾辛基證券交易所(OMX-Helsinki)上市(BIOBV)。
歷史背景
自上世紀(jì)七十年代，必歐瀚(Biohit)公司現(xiàn)任管理者與杰出員工，芬蘭Labsystems(1971年)、Eflab(1978年)及必歐瀚(Biohit) (1988年)創(chuàng)始人Osmo-Suovaniemi教授(M.D,-Ph.D)進(jìn)行了下列發(fā)明，并且使發(fā)明商業(yè)化：
? 9、8及12道可調(diào)式微量移液器。
? 3×3及8×12孔平底微孔板，在每個(gè)孔的底部設(shè)計(jì)了光學(xué)窗孔，作為免疫分析時(shí)的固相物質(zhì)使用。
? 垂直光測(cè)量原理(垂直光路光度學(xué)、濁度分析法、熒光比色法及熒光測(cè)定法)，以及應(yīng)用此項(xiàng)發(fā)明生產(chǎn)的設(shè)備，如最早的96孔板閱讀器Titertek Multiskan(1978)。
? 以微孔板為基礎(chǔ)的酶聯(lián)免疫測(cè)定，比如結(jié)腸直腸癌及HIV診斷與篩選試劑盒，以及早在上試劑80年代就已發(fā)明使用的TORCH-組檢測(cè)試劑盒等。
如今，必歐瀚(Biohit)公司與多通道液體操作技術(shù)、微孔板及垂直光測(cè)定技術(shù)相關(guān)的發(fā)明已被成功地在全球范圍內(nèi)廣泛應(yīng)用，從而已被公認(rèn)為全球行業(yè)標(biāo)準(zhǔn)。上述發(fā)明也在全球范圍內(nèi)掀起了實(shí)驗(yàn)室常規(guī)改革的高潮。
從上世紀(jì)80年代開(kāi)始，必歐瀚(Biohit)公司繼續(xù)開(kāi)展在垂直光測(cè)量工具與微量培養(yǎng)板應(yīng)用領(lǐng)域的研究與開(kāi)發(fā)。以多通道液體操作及垂直測(cè)量工具為基礎(chǔ)的設(shè)備與分析系統(tǒng)，大大拓寬了

Biohit HealthCare is a globally operating biotechnology company that develops, manufactures and markets diagnostic tests and analysis systems.

Our products are used by research and health care worldwide.
Established in 1988 by Professor Osmo Suovaniemi
Business area: Diagnostics
Headquartered in Finland, Helsinki
Subsidiaries located in China and UK
Production plant ís located in Finland
Biohit's products are sold by many distributors around the world
Biohit Plc's share (BIOBV) is quoted on NASDAQ OMX Helsinki since June1999, Small cap/Healthcare

Innovations and patents

Biohit HealthCare's operations are based on a goal-oriented and long-term innovation and patenting strategy. Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract.

Diagnostics

Biohit HealthCare has products and analysis systems for the early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of fecal occult intestinal bleeding (faecal occult blood) that indicates a risk of colorectal cancer. The Acetium innovation was developed to reduce carcinogenic acetaldehyde in the gastrointestinal tract. The key objective of the diagnostics business is to prevent diseases of the gastrointestinal tract.

Biohit Group worldwide

The Biohit Group employs around 35 people in four countries. The company is headquartered in Helsinki, Finland, and has subsidiary in the UK. Additionally, Biohit's products are sold by many distributors around the world.

Biohit Plc. on the stock exchange

Biohit's series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small cap/Healthcare since 1999. More information about the share and financials is available in the Investors section of this site.